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In order to identify new compounds to treat Chagas disease during the acute phase with higher activity
and lower toxicity than the reference drug benznidazole (Bz), two hydroxyphthalazine derivative
compounds were prepared and their trypanocidal effects against Trypanosoma cruzi were evaluated by
light microscopy through the determination of IC50 values. Cytotoxicity was determined by ﬂow
cytometry assays against Vero cells. In vivo assays were performed in BALB/c mice, in which the para-
sitemia levels were quantiﬁed by fresh blood examination; the assignment of a cure was determined by
reactivation of blood parasitemia levels after immunosuppression. The mechanism of action was eluci-
dated at metabolic and ultra-structural levels, by 1H NMR and TEM studies. Finally, as these compounds
are potentially capable of causing oxidative damage in the parasites, the study was completed, by
assessing their activity as potential iron superoxide dismutase (Fe-SOD) inhibitors. High-selectivity
indices observed in vitro were the basis of promoting one of the tested compounds to in vivo assays.
The tests on the murine model for the acute phase of Chagas disease showed better parasitemia inhi-
bition values than those found for Bz. Compound 2 induced a remarkable decrease in the reactivation of
parasitemia after immunosuppression. Compound 2 turned out to be a great inhibitor of Fe-SOD. The
high antiparasitic activity and low toxicity together with the modest costs for the starting materials
render this compound an appropriate molecule for the development of an affordable anti-Chagas agent.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
American trypanosomiasis is a potentially life-threatening
parasitic disease caused by Trypanosoma cruzi. There are more
than 10e20 million people infected worldwide, mostly in Latin
America. Although not a uniform death sentence, T. cruzi infection
is far from innocuous, as an estimated 30e40% of infected in-
dividuals develop debilitating and chronic disease, and this infec-
tion accounts for 20,000e50,000 deaths per year (Tarleton and
Curran, 2012). Currently, the available drugs used for the treat-
ment of this infection, Benznidazole (Bz) or nifurtimox, show
limited therapeutic potential and are associated with serious side
effects, such as skin rashes, leucopoenia, neurotoxicity, fever,oreno).
Ltd on behalf of Australian Society farticular and muscular pain, peripheral neuropathy, lymphade-
nopathy, agranulocytosis, and thrombocytopenic purpura
(Wilkinson et al., 2008; Urbina, 2010). Thus, there is an urgent need
for the development of new anti-trypanosomal agents with lower
toxicity and greater activity, especially for the chronic phase of the
disease. To date, no vaccine has been developed against T. cruzi
(Dumonteil, 2009). Therefore, the search for new targets for
chemotherapy and vaccines is a major challenge. Among the tar-
gets, the parasite antioxidant system has attracted attention due to
its uniqueness in the trypanosomatids.
Taking into account this need for new drugs to combat T. cruzi
parasites and considering the previous experience that our group
has with this type of chemical structures, the imidazole-based
alkylaminophthalazine derivatives (Sanchez-Moreno et al., 2012).
In that occasion, we found that the monoalkylaminophthalazine
were the more active structures against the acute phase of Chagas
disease and we also found out that they were good inhibitors of theor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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considered studying the activity of two hydroxyphthalazine de-
rivatives obtained from the previous selected compounds. In this
particular, they were chemically modify to include a hydroxyl
group in the main ring, this modiﬁcation functionalized the
molecule increasing its solubility and also giving the molecule an
easier ability to future modiﬁcations and introduction of new
groups. These compounds are quite interesting since their syn-
thesis starts form cheap substrates and the procedures are not very
complicated in most of the cases. In this work, their anti-
proliferative activity and unspeciﬁc mammalian cytotoxicity in
the species considered were evaluated in vitro, and these measures
were complemented by infectivity assays on Vero cells. Further-
more, those in whom in vitro activity showed remarkable effects
were tested in vivo. Finally, the parasites were submitted to a
thorough study of the possible mechanisms of action of the com-
pounds assayed, as follows: (i) an 1H NMR study concerning the
nature and percentage of metabolite excretion was performed in
order to obtain information on the inhibitory effect of the com-
pounds on the glycolytic pathway, since it represents the primary
source of energy for the parasite, (ii) alterations caused in the cell
ultrastructure of the parasites were recorded using transmission
electronic microscopy (TEM), and (iii) an enzymatic study of inhi-
bition over the iron superoxide dismutase (Fe-SOD), which repre-
sent one of the many mechanisms of antioxidant defence in
trypanosomatids.2. Materials and methods
2.1. Chemistry
Samples of the tested hydroxyphthalazine derivatives 1 and 2
have been donated by the Heterocyclic Synthetic Receptors
research group of the Organic Chemistry Department at the Uni-
versidad Complutense of Madrid (Sanchez-Moreno et al., 2012,
Fig. 1). They are part of a series of compounds that are being
currently designed by that group, and their synthesis, character-
ization and further antiparasitic properties will be described
elsewhere.2.2. Parasite strain culture
T. cruzi SN3 strain of IRHOD/CO/2008/SN3 was isolated from
domestic Rhodnius prolixus; biological origin is Guajira (Colombia)
(Tellez-Meneses et al., 2008). Epimastigote forms were grown in
axenic Grace's insect medium (Gibco) supplemented with 10%
inactivated foetal bovine serum (FBS) at 28 C in tissue-culture
ﬂasks, Roux ﬂasks (Corning, USA) with a surface area of 75 cm2,
as described by Gonzalez et al. (2005).Fig. 1. Chemical structure of2.3. Transformation of epimastigotes to metacyclic forms
Metacyclogenesis was induced by culturing a 5-day-old culture
of epimastigote forms of T. cruzi that was harvested by centrifu-
gation at 7000 g for 10 min at 10 C according to (Cardoso and
Soares, 2010).
2.4. Cell culture and cytotoxicity tests
Vero cells (Flow) were grown in RPMI and MEM (Gibco), sup-
plemented with 10% iFBS and the procedure followed was as in
Magan et al. (2005).
2.5. In vitro activity assays, extracellular forms
2.5.1. Epimastigotes assay
T. cruzi epimastigotes were collected in the exponential growth
phase and distributed in culture trays (with 24 wells) at a ﬁnal
concentration of 5  104 parasites/well. The effects on the parasite
growth were tested according to Olmo et al. (2013).
2.5.2. Blood trypomastigote forms assay
Compounds 1 and 2 were also evaluated in blood trypomasti-
gotes of T. cruzi. BALB/c femalemice infectedwith T. cruziwere used7
days after infection. Blood was obtained by cardiac puncture using
3.8% sodium citrate as an anticoagulant in a 7:3 blood:anticoagulant
ratio. The parasitaemia in the infected mice was about 1  105 par-
asites/mL. The compounds were diluted in phosphate-buffered sa-
line solution (PBS) to give a ﬁnal concentration 10, 25, and 50 mM for
each product. Aliquots (20 mL) of each solutionweremixed in culture
trays (96wells) with 55 mL of infected blood containing the parasites
at a concentration of approximately 1  106 parasites/mL. Infected
bloodwithPBS, at the sameconcentrations as theproducts,wasused
as control. The plates were shaken for 10 min at room temperature
and kept at 4 C for 24 h. Each solution was examined microscopi-
cally (Olympus CX41) for parasite counting using the Neubauer
haemocytometric chamber (a dilution of 1:100 in PBSwas necessary
to get into the range of counting). The activity (percent of parasites
reduction) was compared with that of the control.
2.6. In vitro activity assays, intracellular forms: amastigotes assay
Vero cells were cultured in RPMI medium supplemented with
10% iFBS, in a humidiﬁed 95% air and 5% CO2 atmosphere at 37 C.
Then the cells were infected and treated as in Gonzalez et al. (2005).
2.7. Infectivity assay
Vero cells were cultured in RPMI medium supplemented with
10% iFBS as described above. Afterward, the cells were infectedthe compounds assayed.
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10:1. The assay was performed as in Gonzalez et al. (2005).
2.8. In vivo trypanosomicidal activity assay
2.8.1. Mice infection and treatment
This experiment was performed with the approval of the Ethical
Committee of the University of Granada, Spain. Two groups of six
BALB/c albino female mice (68 weeks old, 2530 g weight) were
maintained with water and standard chow ad libitum, under a 12-h
dark/light cycle and 22 ± 3 C temperature. Each mouse was
inoculated by intraperitoneal route with 5  105 blood trypomas-
tigotes of T. cruzi obtained from previously infected mice blood.
Group I was positive control group (mice infected but not treated)
and group II was study group (mice infected and treated with the
compounds under study). On seventh day of infestation was begun
the administration of the selected compounds at doses of 25 mg/kg
body mass per day for 5 consecutive days (712 days post-
infection). Parasitemia levels were evaluated from peripheral
blood obtained from the mandibular vein of each mouse (5 mL
samples) and dissolved in 495 mL of a PBS solution at a dilution of
1:100. The circulating parasite numbers were quantiﬁed with a
Neubauer's chamber for counting blood cells and the number of
bloodstream forms was expressed as parasites/mL. This counting
was performed every 3 days during a 40 day period (acute phase)
(Olmo et al., 2014).
2.8.2. Cyclophosphamide-induced immune suppression and
assessment of cure
After day 60, parasitaemia showed progressively decreasing
levels and it is established that the animals entered the chronic
phase of the experiment. Therefore, on day 120, parasitaemia was
shown to be undetectable by fresh blood microscopic examina-
tion, and the mice received 4 intraperitoneal injections of 200 mg/
kg of body mass of cyclophosphamide monohydrate (CP) (ISO-
PAC®) on alternate days, as previously described (Cencig et al.,
2011). Seven days after of the last CP injection, parasitaemia was
evaluated according to the procedure described for acute phase to
quantify the presence of blood trypomastigote forms as reac-
tivation rate. Finally, mice were bled out, under gaseous anaes-
thesia (CO2), via heart puncture and blood was collected. To
obtain the serum, blood was incubated for 2 h/37 C and then
overnight/4 C, followed by centrifuging the supernatant twice at
1000 and 2700 g, consecutively. The serum was aliquoted and
used for ELISA and biochemical analysis, as explained below.
Hearts were harvested and immediately ﬂushed free of blood by
gentle infusion of 10 ml of pre-warmed PBS through the left
ventricle (Ye et al., 2008) in order to avoid contamination of the
collected tissue with blood parasites. After this, samples were
frozen at 80 C and stored until used for DNA extraction (Olmo
et al., 2014).
2.8.3. ELISA tests
Fe-SOD excreted from the parasite, cultured and processed as
described in Lopez-Cespedes et al. (2012), was used as the antigen
fraction. The ELISA test to measure the antibodies against T. cruzi
used was performed as in Olmo et al. (2014).
2.8.4. Toxicity tests by clinical chemistry measurements
A fraction of the serum obtained as it was shown above was
send to the Biochemical service in the University of Granadawhere
a series of parameters were measured according to their com-
mercial kits acquired from Cromakit® by BS-200 Chemistry
Analyzer Shenzhen Mindray (Bio-medical Electronics Co., LTD).
With the levels obtained for different populations of sera (n ¼ 15,n ¼ 6) we calculated the mean value and standard deviation.
Finally, we also calculated the conﬁdence interval for the mean
normal populations based on a conﬁdence level of 95%
(100  (1a) ¼ 100  (10.05)%). The ranges obtained are shown
in Table 2, which allows comparison and analysis of the sera
studied in this work.2.9. Assays to ﬁgure out the mechanism of action
2.9.1. Metabolite excretion
Cultures of T. cruzi epimastigote forms (initial concentration of
5  105 cells/mL) received IC25 of the compounds (except for the
control cultures). After incubation for 96 h at 28 C, the cells were
centrifuged at 400 g for 10 min. The supernatants were collected
in order to determine the excreted metabolites through 1H NMR,
and the chemical shifts were expressed in parts per million
(ppm), using dimethyl sulphoxide (DMSO) as the reference signal.
One-dimensional 1H NMR spectra were acquired on VARIAN
DIRECT DRIVE 400 MHz Bruker spectrometer with AutoX probe
using D2O. The assignments of metabolites were based on 1D
NMR spectrum. The chemical shifts used to identify the respec-
tive metabolites were consistent with those described previously
by our group (Fernandez-Becerra et al., 1997). In addition, the
human metabolome database (http://www.hmdb.ca/) was also
used for this purpose. The spectral region of 1.0e5.5 ppm was
bucketed into a frequency window of 0.1 ppm. The region cor-
responding to water (4.5e5.5 ppm) was excluded during binning
to avoid artefacts due to pre-saturation of water, and the region
corresponding to glucose (3.4e3.8 ppm) was also excluded. The
aromatic region was excluded because the signal to noise ratio in
this region was poorer compared to that of the aliphatic region.
The peak (2.6 ppm) corresponding to DMSO was removed before
binning. The resulting integrals were normalised to the working
region (1.0e3.4) ppm of the spectrum to correct for inter-sample
differences in dilution. The binning and normalisations were
achieved using Mestrenova 9.0 software. The matrix obtained in
Mestrenova was imported to Microsoft Excel for further data
analyses.2.9.2. Ultrastructural alterations
The parasites were cultured at a density of 5  105 cells/mL in
each corresponding medium containing the compounds tested at
the concentration of IC25. After 96 h, these cultures were centri-
fuged at 400 g for 10 min and the pellets produced were washed in
PBS before being mixed with 2% (v/v) paraformaldehyde/glutaral-
dehyde in 0.05 M cacodylate buffer (pH 7.4) for 24 h at 4 C.
Following this, the pellets were prepared for transmission electron
microscopy study using a technique described by our group
(Gonzalez et al., 2005).2.9.3. Superoxide dismutase inhibition assay
The parasites cultured as described above were centrifuged. The
pellet was suspended in 3 mL of STE buffer (0.25 M sucrose, 25 mM
TriseHCl, 1 M EDTA, pH 7.8) and disrupted by three cycles of sonic
disintegration, 30 s each at 60 W. The sonicated homogenate was
centrifuged at 1500 g for 5 min at 4 C, and the pellet was washed
three times in ice-cold STE buffer to continue with the supernatant.
This fraction was centrifuged (2500 g for 10 min at 4 C) and the
supernatant was collected. The protein concentrations were
determined using the Bradford method (Bradford, 1972). Iron and
copperezinc superoxide dismutases (Fe-SOD and CuZn-SOD) ac-
tivities were determined using the method described by Beyer and
Fridovich (Beyer and Fridovich, 1987).
Table 1
In vitro activity, toxicity and selectivity index found for the compounds and the reference drug on extracellular and intracellular forms of Trypanosoma cruzi.













Bz 15.8 ± 1.1 23.3 ± 4.6 22.4 ± 1.9 13.6 ± 0.9 0.8 0.6 0.6
Comp 1 39.2 ± 2.1 20.8 ± 1.7 29.5 ± 0.8 148.8 ± 3.1 4 (5) 7 (12) 5 (8)
Comp 2 8.5 ± 5.7 7.4 ± 2.2 10.8 ± 0.8 214.7 ± 4.6 25 (31) 29 (48) 20 (33)
In brackets: number of times that compound SI exceeds the reference drug SI. Results are averages of three separate determinations.
a IC50¼ the concentration required to give 50% inhibition, calculated by linear regression analysis from the Kc values at concentrations employed (1, 10, 25, 50 and 100 mM).
b Towards cell vero after 72 h of culture.
c Selectivity index ¼ IC50 cell vero/IC50 extracellular and intracellular form of parasite.
Table 2
Summarizes the Biochemical clinical parameters tested in different groups of BALB/c Mice infected with Trypanosoma cruzi at different experimental situations.
Kidney markers proﬁle Liver markers proﬁle
Urea (mg/dL) Uric acid (mg/dL) AST/GOT (U/L) ALT/GPT (U/L) Total bilirubin (mg/dL) Phosphatase alkalyne (U/L)
Uninfected mice (n ¼ 15) 39 [36e43] 5 [4.3e5.5] 126 [103e148] 46 [37e54] 0.23 [0.17e0.28] 133 [104e161]
Infected mice-acute phase (n ¼ 15) 49 [39e60] 4.5 [3.7e5.5] 129 [100e157] 48 [38e58] 0.15 [0.12e0.18] 231 [161e300]
Infected mice-chronic phase (n ¼ 15) 49 4.3 148 53 0.12 186
120 days post infection mice and
Comp 2125 mg/kg$w treated (n ¼ 6)
¼ ¼ þ þ þ ¼
Key:¼, variation no larger than 10%;þ, up to 10% of increasing over the range;þþ, up to 30% of increasing over the range;þþþ, up to 40% of increasing over the range;þþþþ,
more than 50% of increasing over de range; -, up to 10% of decreasing over the range; - -, up to 30% of decreasing over the range; - - -, up to 40% of decreasing over the range; - -
- -, more than 50% of decreasing over de range.
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3.1. In vitro trypanosomicidal evaluation
In order to get preliminary information, in vitro activities of 1
and 2 were evaluated against epimastigote, amastigote and trypo-
mastigote forms of T. cruzi, as shown in Table 1. It was found that the
more sensitive forms to all different compounds tested were the
intracellular forms (amastigotas) reaching an effectiveness of 48
times higher than the reference drug in the case of 2. The com-
pound 1 also showed trypanosomicidal activity against the
different forms of the parasite and the effect was always better than
that of the reference drug; however, against all forms it showed less
than 15 times effectiveness compared with Bz. As a result, com-
pound 2 was chosen to undergo an extra in vitro assay and deeper
insight of the activity of this compound was found in the infectivity
assay, where the process that takes place in the host of the lifecycle
of T. cruzi in the presence of the drugs was reproduced in vitro. Once
again, 2 was found to be the more active than the reference drug,
decreasing the rate of infection in cells by 80% on the last day of the
experiment, as shown in Fig. 2A. It also decreased the average
number of amastigote forms found per infected cell; these de-
creases reached the 57% for cells treatedwith 2 beingmore efﬁcient
than Bz, which effectively only decreased the number by 15%
compared to the control (Fig. 2B). The last data obtained from this
assay were regarding the number of trypomastigote forms released
by the infected cells, as can be seen in Fig. 2C, where the effect
showed a signiﬁcant decrease of 43% compared to the control assay.
3.2. In vivo trypanosomicidal evaluation
Since compound 2 showed remarkable selectivity index (SI,
mammalian cells IC50/parasite IC50) values with respect to Bz in the
in vitro experiments, it was selected for being close to the criteria
established by Nwaka et al., 2011 for further in vivo studies in the
chosen murine model. Its trypanozidal activity during the acute
phase of Chagas disease [until 40 days post-infection (pi)] was ﬁrst
investigated. None of the animals treated with either the control orcompound 2 died during the treatment. As shown in Fig. 3, the
reduction of parasitaemia in mice treated with the compound was
evident from the very beginning of the treatment and was main-
tained until the end, resulting in parasitaemia reduction with
respect to the control experiment for Bz and 2.
The next step was to evaluate the behaviour of the compound
until the chronic phase. Therefore, the mice treated with the
compound under study during the acute phase as described in the
material and methods section, were taken up to day 120 pi
(advanced chronic phase). In order to evaluate the immune status
and the disease extent of the mice at the chronic phase the mice
were immunosuppressed as it has been explained in section 2.8.2;
then, blood samples were extracted for determining parasitaemia
and immunoglobulin G (Ig-G) levels in comparison with the cor-
responding non-immunosuppressed (control) subgroup of mice
(Fig. 4). Concerning the parasitaemia reactivation, Fig. 4A shows a
graph indicating the percentage of parasitaemia reactivation for 2
in comparison with the control mice; lower percentages were ob-
tained in the treated case with 54.1% of reactivation, whereas a
reactivation of 80.3% was found in the control mice.
The enzyme-linked immunosorbent assay (ELISA) was used for
the detection of total Ig-G levels and the antigen source was the Fe-
SOD enzyme isolated in our laboratory. The detection of total Ig G
allowed evaluation of the immune status of the mice (el Bouhdidi
et al., 1994), since that indicates the level of protection that
should be attributed to the tested compounds, combined with the
innate protection that mice have naturally (Kayama and Takeda,
2010). Results obtained from the ELISA experiments were
conﬁrmed by the parasitaemia assay performed as indicated above.
In accordance with the ELISA test, the group of mice treated with
compound 2 almost maintained levels of total Ig G (Fig. 4B), as did
chronic infected mice, lower than that of the control group after
being immunosuppressed, while the control group levels were
increased as a consequence of the reactivation of parasitaemia.
Clinical chemistry measurements are provided in Table 2. The
changes in the transaminases and the total bilirubin, that were
observed for the group of mice treated with 2, were the only dif-
ferences found when compared to the control group, but these
Fig. 2. Reduction of the infectivity of T. cruzi in Vero cells treated with 2 and Bz. (A)
Rate of infection, (B) mean number of amastigotes per infected Vero cell and (C)
number of trypomastigotes in the culture medium. Concentration used was the IC25:
6 mM for 2 and 8.5 mM for Bz Values are the means of three separate experiments.
Fig. 4. Immunosuppression in vivo assay for mice untreated and treated with 125 mg/
kg of body mass of 2. (A) Shows the reactivation of blood parasitemia after the
immunosupression cycles by fresh blood counting comparing to the peak level of
parasitemia reached by each group during acute phase. (B) Shows differences in the Ig
G levels measured by ELISA at different day post infection for immunosuppressed and
non-immunosuppressed group of mice.
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conﬁrms the evidence that the compounds tested are not toxic in
the murine model; in fact, this lack of toxicity added to the better
efﬁcacy of 2, leading us consider this compound as a promisingFig. 3. Parasitemia in the murine model of acute Chagas disease. Grey shade repre-
sents the treatment days.candidate for the treatment of Chagas disease. Therefore, the
compound should be followed-up in future clinical experiments.
3.3. Possible mechanism of action
Trypanosomatids are unable to completely degrade glucose to
CO2, so they excrete part of the hexose skeleton into the medium as
partially oxidised fragments, the nature and percentage of which
depend on the pathway used for glucose metabolism (Ginger,
2005). The catabolism products in T. cruzi are mainly succinate,
acetate, D-lactate and L-alanine (Cazzulo, 1992). In order to obtain
some information about the effects of 2 on the glucose metabolism
of the parasite, we registered the 1H NMR spectra of T. cruzi epi-
mastigotes treated with the test compounds (spectra not shown);
the ﬁnal excretion products were identiﬁed qualitatively and
quantitatively, and the results obtained were compared with those
found for untreated control epimastigotes. Fig. 5 shows the differ-
ences found in every case with respect to the control.
Excretion of almost all metabolites was disturbed in the treat-
ment with 2, with succinate being the most affected, showing an
increase of 90%, followed by acetate and D-lactate with decreases of
31% and increases of 12%, respectively. All of these data could be
interpreted on the basis of a change in the succinate, D-lactate,
pathways occurring in the presence of the compound under
investigation. It is well known that D-lactate is formed mainly by
the methylglyoxal bypass and L-alanine originate from the trans-
formation of pyruvate in the presence of alanine aminotransferase
(Wyllie and Fairlamb, 2011; Bringaud et al., 2006). On the other
hand, it is interesting to note that the increase in succinate indicate
catabolic changes that could be related to a malfunction of the
mitochondria, due to the redox stress produced by inhibition of the
mitochondrion-resident Fe-SOD enzyme (Kirkinezos and Moraes,
Fig. 5. Variation percentages in the height of the peaks corresponding to catabolites
excreted by T. cruzi epimastigotes in the presence of 2 at IC25, compared to a control
sample after 96 h of incubation. Fig. 7. In vitro inhibition (%) of CuZn-SOD from human erythrocytes and Fe-SOD from
T. cruzi epimastigotes for compound 2 (Cu/Zn-SOD activity 23.36 ± 4.21 U/mg) (Fe-SOD
activity 20.77 ± 3.18 U/mg). Differences between the activities of the control homog-
enate and those ones incubated with compounds were obtained according to the
NewmaneKeuls test. IC50 values are shown in brackets. Values are the average of three
separate determinations.
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consequent decrease of the succinate produced in mitochondria.
Overall, these data should conﬁrm that themodiﬁcations generated
in organelles like glycosomes or mitochondria by the compounds
assayed are the ultimate reason for the alterations observed in the
excreted products of T. cruzi.
Modiﬁcations at the ultrastructural level caused after incubation
of epimastigote forms of T. cruziwith the compound under study in
the current work, 2, have been studied. This compound induced
strong disturbances in the parasites' morphology and consequently
death in some cases. At this level, 2 was found to be the more
effective compound, causing more mortality in the parasite cul-
tures compared to the control when the IC25 was administered. The
parasites were clearly morphologically disturbed when compared
with the untreated assay, as shown in Fig. 6. Among the more
common disturbances when 2was added to the medium, as shown
in Fig. 6, include the ﬁnding that mitochondria were swollen,
without cristae and almost unrecognisable; the cytoplasmwas also
full of small vacuoles, there was a lack of ribosomes and low elec-
tron density was appreciated.
These in vitro and in vivo results prompted us to evaluate the
inhibitory effect of compound 2 on SOD activity to test their po-
tential as enzyme inhibitors. The results obtained are shown in
Fig. 7, with the corresponding IC50 values that were calculated.Fig. 6. Ultrastructural alterations shown by TEM in epimastigotes of T. cruzi treated with 2 at
mitochondria (M), glycosomes (G), microtubules (MT), vacuoles (V), reservosomes (R), kineSigniﬁcant inhibitory values of Fe-SOD activity were found for the
tested compound. Compound 2 showed values close to 100% inhi-
bition at 100 mM, with IC50 values around 27 mM. The design of an
effective drug that is able to inhibit parasite Fe-SOD without
inhibiting human Cu/Zn-SOD is an interesting goal. Therefore, we
also assayed the effect of the compound 2 on Cu/Zn-SOD in human
erythrocytes. The results obtained showed that the inhibition per-
centages for human Cu/Zn-SOD were lower than for Fe-SOD.
Therefore, 162 mM of the studied compound was needed to give a
50% of inhibition.
In conclusion, the trypanocidal properties of compounds 1 and 2
have been examined both in vivo and in vitro. The two compounds
of the present study were chemical modiﬁcations of the most
efﬁcient compounds previously tested by our group (Sanchez-
Moreno et al., 2012). As in the ﬁeld of medicinal chemistry, any
modiﬁcations within the structure of the compounds makes that it
had to restart the assays from the very ﬁrst phase. The purpose of
this change was the inclusion of a hydroxy group in one of the rings
of the pthalazine, this group besides being a new structure with
higher polar properties allows for future chemical conjugation toIC25 concentration. (1) Control parasite showing typical organelles such as nucleus (N),
toplast (K) and ﬂagellum (F). (1) Untreated. (2) Treated with 2. Scale bar ¼ 1 mm.
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improve the tripanozidal activity in vitro, it was found that in vivo
the toxicity was greatly reduced and therefore permit the admin-
istration of higher doses. Also, once again revealed that these
chemical structures highly inhibit the parasite enzyme Fe-SOD, as it
was anticipated in molecular modelling studies previously per-
formed, (Sanchez-Moreno et al., 2012) conﬁrming once again to be
the target for these compounds.
The experiments allowed us to select compound 2, which dis-
played improved efﬁciency and lower toxicity than the reference
drug. Parallel studies have been carried to establish the mecha-
nisms of action. Compound 2 selectively inhibits the Fe-SOD
enzyme of the parasite. Moreover, compound 2 showed an in vivo
failure of reactivation in parasitaemia after immunosuppression at
a dosage of 125 mg/kg body mass. Finally, owing to their promising
activity, a further high-level study should be considered to obtain
an improved efﬁciency.
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